These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 24746855)

  • 1. The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse.
    Savolainen MH; Richie CT; Harvey BK; Männistö PT; Maguire-Zeiss KA; Myöhänen TT
    Neurobiol Dis; 2014 Aug; 68():1-15. PubMed ID: 24746855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the α-Synuclein Virus Vector-Based Parkinson's Disease Mouse Model by Decreasing α-Synuclein Oligomeric Species in Mouse Brain.
    Svarcbahs R; Julku UH; Myöhänen TT
    J Neurosci; 2016 Dec; 36(49):12485-12497. PubMed ID: 27927963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolyl oligopeptidase inhibition attenuates the toxicity of a proteasomal inhibitor, lactacystin, in the alpha-synuclein overexpressing cell culture.
    Myöhänen TT; Norrbacka S; Savolainen MH
    Neurosci Lett; 2017 Jan; 636():83-89. PubMed ID: 27818354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.
    Myöhänen TT; Hannula MJ; Van Elzen R; Gerard M; Van Der Veken P; García-Horsman JA; Baekelandt V; Männistö PT; Lambeir AM
    Br J Pharmacol; 2012 Jun; 166(3):1097-113. PubMed ID: 22233220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolyl oligopeptidase enhances α-synuclein dimerization via direct protein-protein interaction.
    Savolainen MH; Yan X; Myöhänen TT; Huttunen HJ
    J Biol Chem; 2015 Feb; 290(8):5117-5126. PubMed ID: 25555914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of prolyl oligopeptidase increases the survival of alpha-synuclein overexpressing cells after rotenone exposure by reducing alpha-synuclein oligomers.
    Dokleja L; Hannula MJ; Myöhänen TT
    Neurosci Lett; 2014 Nov; 583():37-42. PubMed ID: 25240592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolyl oligopeptidase inhibition by KYP-2407 increases alpha-synuclein fibril degradation in neuron-like cells.
    Rostami J; Jäntti M; Cui H; Rinne MK; Kukkonen JP; Falk A; Erlandsson A; Myöhänen T
    Biomed Pharmacother; 2020 Nov; 131():110788. PubMed ID: 33152946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolyl oligopeptidase acts as a link between chaperone-mediated autophagy and macroautophagy.
    Cui H; Norrbacka S; Myöhänen TT
    Biochem Pharmacol; 2022 Mar; 197():114899. PubMed ID: 34968496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Removal of prolyl oligopeptidase reduces alpha-synuclein toxicity in cells and in vivo.
    Svarcbahs R; Julku UH; Norrbacka S; Myöhänen TT
    Sci Rep; 2018 Jan; 8(1):1552. PubMed ID: 29367610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of prolyl oligopeptidase inhibitors on alpha-synuclein aggregation and autophagy cannot be predicted by their inhibitory efficacy.
    Kilpeläinen TP; Hellinen L; Vrijdag J; Yan X; Svarcbahs R; Vellonen KS; Lambeir AM; Huttunen H; Urtti A; Wallen EAA; Myöhänen TT
    Biomed Pharmacother; 2020 Aug; 128():110253. PubMed ID: 32447211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolyl oligopeptidase inhibition reduces alpha-synuclein aggregation in a cellular model of multiple system atrophy.
    Cui H; Kilpeläinen T; Zouzoula L; Auno S; Trontti K; Kurvonen S; Norrbacka S; Hovatta I; Jensen PH; Myöhänen TT
    J Cell Mol Med; 2021 Oct; 25(20):9634-9646. PubMed ID: 34486218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New tricks of prolyl oligopeptidase inhibitors - A common drug therapy for several neurodegenerative diseases.
    Svarcbahs R; Julku U; Kilpeläinen T; Kyyrö M; Jäntti M; Myöhänen TT
    Biochem Pharmacol; 2019 Mar; 161():113-120. PubMed ID: 30660495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extracellular prolyl oligopeptidase derived from activated microglia is a potential neuroprotection target.
    Natunen TA; Gynther M; Rostalski H; Jaako K; Jalkanen AJ
    Basic Clin Pharmacol Toxicol; 2019 Jan; 124(1):40-49. PubMed ID: 29998529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolyl oligopeptidase inhibition activates autophagy via protein phosphatase 2A.
    Svarcbahs R; Jäntti M; Kilpeläinen T; Julku UH; Urvas L; Kivioja S; Norrbacka S; Myöhänen TT
    Pharmacol Res; 2020 Jan; 151():104558. PubMed ID: 31759088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Removal of proteinase K resistant αSyn species does not correlate with cell survival in a virus vector-based Parkinson's disease mouse model.
    Eteläinen TS; Kilpeläinen TP; Ignatius A; Auno S; De Lorenzo F; Uhari-Väänänen JK; Julku UH; Myöhänen TT
    Neuropharmacology; 2022 Nov; 218():109213. PubMed ID: 35964686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single pathway targets several health challenges of the elderly.
    Bahr BA
    Rejuvenation Res; 2014 Aug; 17(4):382-4. PubMed ID: 24953230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KYP-2047 penetrates mouse brain and effectively inhibits mouse prolyl oligopeptidase.
    Jalkanen AJ; Leikas JV; Forsberg MM
    Basic Clin Pharmacol Toxicol; 2014 Jun; 114(6):460-3. PubMed ID: 24350801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prolyl oligopeptidase inhibitor reduces tau pathology in cellular models and in mice with tauopathy.
    Eteläinen TS; Silva MC; Uhari-Väänänen JK; De Lorenzo F; Jäntti MH; Cui H; Chavero-Pieres M; Kilpeläinen T; Mechtler C; Svarcbahs R; Seppälä E; Savinainen JR; Puris E; Fricker G; Gynther M; Julku UH; Huttunen HJ; Haggarty SJ; Myöhänen TT
    Sci Transl Med; 2023 Apr; 15(691):eabq2915. PubMed ID: 37043557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavioural and dopaminergic changes in double mutated human A30P*A53T alpha-synuclein transgenic mouse model of Parkinson´s disease.
    Kilpeläinen T; Julku UH; Svarcbahs R; Myöhänen TT
    Sci Rep; 2019 Nov; 9(1):17382. PubMed ID: 31758049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition-mediated changes in prolyl oligopeptidase dynamics possibly related to α-synuclein aggregation.
    Walczewska-Szewc K; Rydzewski J; Lewkowicz A
    Phys Chem Chem Phys; 2022 Feb; 24(7):4366-4373. PubMed ID: 35112120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.